Hims & Hers Health (NYSE:HIMS) Stock Price Down 10.5% - Time to Sell?

Key Points

• Hims & Hers Health's stock dropped by 10.5% during Friday's trading, closing at $52.96 after trading as low as $52.45, with volume down 48% from its average.
• Recent analyst ratings show a consensus "Reduce" outlook, with two buy ratings, nine hold ratings, and three sell ratings; the average price target is $38.92.
• Insider selling has been significant, with one insider selling over $500,000 worth of shares and a total of 1.56 million shares sold in the past three months.

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report)'s stock price traded down 10.5% during trading on Friday . The company traded as low as $52.45 and last traded at $52.96. 16,866,269 shares changed hands during trading, a decline of 48% from the average session volume of 32,575,076 shares. The stock had previously closed at $59.15.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on HIMS. Citigroup reissued a "sell" rating on shares of Hims & Hers Health in a research report on Monday, June 23rd. Canaccord Genuity Group reiterated a "buy" rating and issued a $68.00 target price on shares of Hims & Hers Health in a report on Friday, September 12th. Zacks Research lowered Hims & Hers Health from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 19th. Wall Street Zen cut Hims & Hers Health from a "buy" rating to a "hold" rating in a report on Monday, July 28th. Finally, Weiss Ratings restated a "hold (c+)" rating on shares of Hims & Hers Health in a research report on Tuesday. Two equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Reduce" and an average price target of $38.92.

Hims & Hers Health Trading Down 14.1%

The stock has a market cap of $11.48 billion, a PE ratio of 63.31, a price-to-earnings-growth ratio of 4.29 and a beta of 2.25. The business has a 50 day moving average of $51.05 and a 200-day moving average of $48.63. The company has a current ratio of 4.98, a quick ratio of 4.46 and a debt-to-equity ratio of 1.72.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its quarterly earnings results on Monday, August 4th. The company reported $0.17 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.18 by ($0.01). The business had revenue of $544.83 million during the quarter, compared to analyst estimates of $550.06 million. Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%.The firm's quarterly revenue was up 72.6% on a year-over-year basis. During the same period in the previous year, the business posted $0.06 earnings per share. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Insider Buying and Selling

In other news, insider Patrick Harrison Carroll sold 10,021 shares of Hims & Hers Health stock in a transaction dated Wednesday, September 17th. The stock was sold at an average price of $50.50, for a total transaction of $506,060.50. Following the completion of the sale, the insider directly owned 169,940 shares in the company, valued at $8,581,970. The trade was a 5.57% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Oluyemi Okupe sold 11,595 shares of Hims & Hers Health stock in a transaction dated Friday, October 3rd. The stock was sold at an average price of $57.72, for a total value of $669,263.40. Following the completion of the transaction, the chief financial officer owned 70,232 shares in the company, valued at $4,053,791.04. The trade was a 14.17% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 1,561,799 shares of company stock valued at $80,686,085. 13.71% of the stock is currently owned by company insiders.

Institutional Trading of Hims & Hers Health

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Signaturefd LLC raised its position in Hims & Hers Health by 17.7% during the first quarter. Signaturefd LLC now owns 2,586 shares of the company's stock worth $76,000 after acquiring an additional 388 shares in the last quarter. Lake Hills Wealth Management LLC acquired a new stake in Hims & Hers Health during the second quarter worth approximately $277,000. Occidental Asset Management LLC bought a new position in shares of Hims & Hers Health during the second quarter worth approximately $305,000. Dakota Wealth Management bought a new position in Hims & Hers Health in the 2nd quarter valued at about $354,000. Finally, Fiduciary Alliance LLC grew its position in Hims & Hers Health by 120.4% in the second quarter. Fiduciary Alliance LLC now owns 109,253 shares of the company's stock valued at $5,446,000 after acquiring an additional 59,686 shares during the last quarter. Institutional investors and hedge funds own 63.52% of the company's stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.